Effective treatment with mepolizumab in a patient with severe eosinophilic granulomatosis with polyangiitis complicated with small intestine perforation

oleh: Mari Sato, Masakiyo Yatomi, Ikuo Wakamatsu, Shogo Uno, Chiharu Hanazato, Tomomi Masuda, Koichi Yamaguchi, Haruka Aoki-Saito, Norimitsu Kasahara, Yosuke Miura, Hiroaki Tsurumaki, Kenichiro Hara, Yasuhiko Koga, Noriaki Sunaga, Takuhisa Okada, Hayato Ikota, Takeshi Hisada, Toshitaka Maeno

Format: Article
Diterbitkan: Elsevier 2023-01-01

Deskripsi

Eosinophilic granulomatosis with polyangiitis (EGPA) is systemic vasculitis caused by eosinophilia affecting small to medium-sized blood vessels, which damages the organs. Antineutrophil cytoplasmic antibody-associated vasculitis EGPA treatment guidelines added anti-interleukin-5 antibody mepolizumab to the standard treatment protocol for active-non-severe EGPA based on the MIRRA study. Nevertheless, the role of mepolizumab in treating patients with active severe EGPA has not been established. We treated a patient with EGPA complicated with small intestine perforation using steroid pulse intravenous, high-dose glucocorticoids, intravenous high-dose immunoglobulin therapy, and mepolizumab without immunosuppression agents; the patient went into remission, suggesting that mepolizumab is an effective therapeutic agent that could lead to remission in severe EGPA.